Chronic Obstructive Pulmonary Disease (COPD) refers to a group of lung diseases including chronic bronchitis and emphysema. It causes persistent symptoms and airflow limitation due to exposure to toxic gases or particles. Inhalers and nebulizers are commonly used to manage COPD symptoms.
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 20.86 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising prevalence of smoking and growing pollution levels have resulted in a marked increase in COPD incidence rates globally. According to the World Health Organization, COPD is projected to become the third leading cause of death worldwide by 2030. With growing COPD patient pools, demand for medications and devices to manage the condition is also witnessing considerable growth. Advancements in portable inhalers and wearable nebulizers further allow for improved treatment convenience and compliance. Increased R&D focus on developing more effective therapeutics for COPD treatment also augurs well for market expansion over the forecast period.
Segment Analysis
The global chronic obstructive pulmonary disease (COPD) treatment market growth is dominated by drug therapies segment. Drugs such as bronchodilators, corticosteroids, and combinations account for majority of the market share due to lower costs and proven efficacy in managing COPD symptoms. Bronchodilators dominate the drug therapies segment due to their extensive use in both relieving symptoms as well as preventing exacerbations.
Key Takeaways
The global chronic obstructive pulmonary disease (COPD) treatment market is expected to witness high growth during the forecast period of 2024 to 2031. The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 20.86 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031.
Regional analysis: North America currently dominates the global COPD treatment market owing to high prevalence and diagnosis rates of COPD in the region. However, Asia Pacific region is expected to grow at the fastest pace due to rapidly improving healthcare infrastructure and increasing pollution levels in densely populated countries such as China and India.
Key players: Key players operating in the chronic obstructive pulmonary disease (COPD) treatment market are First Sensor AG, Bosch Sensortec GmbH, Honeywell International Inc., Murata Manufacturing Co. Ltd., ROHM Co. Ltd., Amphenol Corporation, InvenSense Inc. (TDK Corporation), Sensata Technologies Inc., NXP Semiconductors NV (Freescale), Goertek Inc., TE Connectivity Ltd., STMicroelectronics NV, Infineon Technologies AG, Omron Corporation, and Alps Alpine Co. Ltd.
Get more insights on this topic: https://www.ukwebwire.com/chronic-obstructive-pulmonary-disease-copd-treatment-market-share-and-opportunity-analysis/
The Chronic Obstructive Pulmonary Disease (COPD) was valued at US $10.78 billion in the year 2018 and is estimated to reach US $14.27 billion by 2026, at a CAGR of 3.57%.Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction and breathing difficulties.
Further, COPD symptoms include frequent coughing, increased breathlessness, wheezing and tightness in the chest.The class of drugs for the treatment of COPD includes bronchodilators, leukotriene antagonists, mast cell stabilizers and immunosuppressants.
There were around 251 million cases of COPD reported globally by WHO.
Tobacco smoking is a major risk factor for COPD and approximately 20% of smokers develop the disease and about 15–20 % of COPD cases are due to occupational exposures to pollutants at the workplace.
However, due to a surge in the industrial activities in the Asian Pacific region, especially in China, India, Vietnam, Bangladesh, etc.
Increased automotive, industrial exhaust gases are degrading air quality and have led to the increased incidence of asthma due to immense pollution, especially in the low-income population in the emerging economies.
